Skip to main content
Caplight Logo









Xenocor

Xenocor

Private
Salt Lake City, UtahHealthcare & Life Scienceshttps://xenocor.com/

Last Round

Series A

Apr 18, 2023

Total Funding Raised

$10M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Xenocor is a medical device company that develops and markets single-use, high-definition, fog-free laparoscopic imaging systems for minimally invasive surgical procedures.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Medical Imaging

Business Model

B2B

Customer Profile

Hardware Sales

AI Layer

Non-AI

Keywords

surgical visualizationminimally invasive surgerylaparoscopemedical devicesurgical imagingdisposable laparoscopeendoscopysingle-use medical devicessurgical hardwarevideo processorambulatory surgery centerASCoperating room equipmentsurgical techmedtech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Xenocor Comparables

Compare Xenocor with similar companies based on industry and business-model similarity.

Xenocor comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Outlook Surgical
86%
Contra Healthcare Solutions
80%
Pristine Surgical
77%

Xenocor Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AApr 18, 2023
StrategicJun 22, 2021
AcceleratorJun 15, 2021
Series A ExtensionApr 27, 2021
VC RoundOct 5, 2020

Key People

Founding team and executive leadership

David McNally

Chief Executive Officer

Executive Team

Tony Watson

Chief Commercial Officer, Chief Operating Officer

Executive Team

Xenocor Investors

Notable investors and investment history

Xenocor investors
InvestorRounds
GenHenn CapitalSeries A
MedTech InnovatorAccelerator
Mountain Pacific Venture FundVC Round
Patel Family InvestmentsSeries A
Growing Impact VenturesSeries A Extension

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 20, 2026

    Monthly visitors increased 48% MoM.

  • May 17, 2026

    Grew 33% QoQ from 9 to 12 employees.

Xenocor Filings

Explore SEC and related filing metadata, where available.

Xenocor filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Xenocor's valuation, stock price, and market status.

Is Xenocor a public or private company?

Xenocor is a private company.

What is the current stock price of Xenocor?

Xenocor is a private company with no public stock price. No recent secondary market data is available.

How much is Xenocor worth (valuation)?

Valuation information for Xenocor is not publicly available.

Can I buy Xenocor stock?

Xenocor shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Xenocor's last funding round?

Xenocor's most recent funding round was Series A on April 18, 2023.

Who are the main investors in Xenocor?

Key investors in Xenocor include GenHenn Capital.

Will Xenocor IPO soon?

No public IPO plans have been announced for Xenocor.

How can I track Xenocor secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Xenocor's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersSalt Lake City, Utah
Employee Range11
Year Founded2014
Last FundingApr 18, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?